Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

BMC Cancer

Alexandra Connelly-Frost³  Sumitra Shantakumar²  Monica G Kobayashi²  Haojie Li¹  Li Li¹ 

[1] Department of Worldwide Epidemiology, Research and Development, GlaxoSmithKline, Collegeville, PA, USA

[2] Department of Worldwide Epidemiology, Research and Development, GlaxoSmithKline, 5 Moore Drive, P.O. Box 13398, Research Triangle Park, NC, 17.2116, USA

[3] Frost Consulting, Epidemiologic Research and Grant Writing, 1256 S. Kings Drive, Charlotte, NC, USA

关键词: Deep vein thrombosis;    Pulmonary embolism;    Co-morbidity;    Incidence;    Renal cell carcinoma;    Venous thromboembolism;   

Others  :  1079782
DOI  :  10.1186/1471-2407-13-209

 received in 2012-08-18, accepted in 2013-04-12,  发布年份 2013

【 摘 要 】

Background

Venous thromboembolic co-morbidities can have a significant impact on treatment response, treatment options, quality of life, and ultimately, survival from cancer. The extent of venous thromboembolic co-morbidity among older renal cell cancer patients is poorly described in the literature. It is important to understand the scope of venous thromboembolic events, before and after diagnosis, in order to offer renal cell cancer patients optimal care and improved quality of life.

Methods

The main goal of this study was to estimate and describe the incidence of venous thromboembolic events before and after renal cell cancer diagnosis. SEER-Medicare linked data (1991–2003) was utilized for this retrospective cohort analysis (n = 11,950) of older renal cell cancer patients (≥ 65 years). Incidence rates and proportions in addition to multivariable Cox proportional hazard and logistic regression models were utilized to describe the incidence and relative risk of venous thromboembolic events.

Results

We observed that in the 12 months after diagnosis, 8.3% of renal cell cancer patients experienced a deep venous thrombosis, 2.4% experienced a pulmonary embolism, and 3.9% experienced other thromboembolic events. Nearly 70% of venous thromboembolic events occurred in the first 90 days after renal cell cancer diagnosis. Renal cell cancer patients were 2–4 times more likely to have a venous thromboembolic event in the 12 months after cancer diagnosis than non-cancer patients followed during the same time frame. Recent history of a venous event substantially increased the risk of that same event in the 12 months after diagnosis (HR = 5.2-18.8).

Conclusion

Venous thromboembolic events are common and serious co-morbidities that should be closely monitored in older renal cell cancer patients, particularly during the first 3 months following diagnosis and among those with a recent history of a venous thromboembolic event.

【 授权许可】

   
2013 Connelly-Frost et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343:1846-1850.
• [2]Chew HK, Wun T, Harvey D, Zhou H, White RH: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006, 166:458-464.
• [3]Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007, 5:632-634.
• [4]Lee AY, Levine MN: Venous thromboembolism and cancer: risks and outcomes. Circulation 2003, 107:I17-I21.
• [5]Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E: A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006, 243:89-95.
• [6]Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006, 4:529-535.
• [7]Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH: Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006, 24:484-490.
• [8]Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007, 110:2339-2346.
• [9]Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111:4902-4907.
• [10]Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999, 78:285-291.
• [11]Sallah S, Wan JY, Nguyen NP: Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002, 87:575-579.
• [12]Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE: Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006, 119:60-68.
• [13]Khorana AA, Connolly GC: Assessing risk of venous thromboembolism in the cancer patient. J Clin Oncol 2009, 27(29):4839-47.
• [14]Wun T, White RH: Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009, 27(Suppl 1):63-74.
• [15]Blom JW, Doggen CJ, Osanto S, Rosendaal FR: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293:715-722.
• [16]Sousou T, Khorana A: Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 2009, 29:121-124.
• [17]Anderson FA Jr, Spencer FA: Risk factors for venous thromboembolism. Circulation 2003, 107:I9-16.
• [18]Agnelli G, Becattini C: Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006, 4:1886-1890.
• [19]Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW: An association between atherosclerosis and venous thrombosis. N Engl J Med 2003, 348:1435-1441.
• [20]Prandoni P: Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost 2007, 5(Suppl 1):270-275.
• [21]van der Hagen PB, Folsom AR, Jenny NS, Heckbert SR, O'Meara ES, Reich LM: Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006, 4:1903-1908.
• [22]White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D: Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005, 165:1782-1787.
• [23]Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M: Venous thromboembolism and cancer. Lancet 1998, 351:1077-1080.
• [24]Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998, 338:1169-1173.
• [25]Kessler CM: The link between cancer and venous thromboembolism: a review. Am J Clin Oncol 2009, 32:S3-S7.